Transcriptomic Profile Reveals Deregulation of Hearing-Loss Related Genes in Vestibular Schwannoma Cells Following Electromagnetic Field Exposure.
Cell Movement
/ radiation effects
Cell Proliferation
/ radiation effects
Cell Survival
/ radiation effects
Connexin 26
/ genetics
Electromagnetic Fields
/ adverse effects
Gene Expression Profiling
Gene Expression Regulation
Hearing Loss
/ etiology
Humans
Membrane Proteins
/ genetics
Neurofilament Proteins
/ genetics
Neuroma, Acoustic
/ etiology
Primary Cell Culture
Proteins
/ genetics
Repressor Proteins
/ genetics
Schwann Cells
/ metabolism
Signal Transduction
Transcriptome
GJB2
NEFL
NF2
OTOGL
REST
Schwann cell
TPRN
hearing loss
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
20 07 2021
20 07 2021
Historique:
received:
10
06
2021
revised:
16
07
2021
accepted:
18
07
2021
entrez:
7
8
2021
pubmed:
8
8
2021
medline:
28
10
2021
Statut:
epublish
Résumé
Hearing loss (HL) is the most common sensory disorder in the world population. One common cause of HL is the presence of vestibular schwannoma (VS), a benign tumor of the VIII cranial nerve, arising from Schwann cell (SC) transformation. In the last decade, the increasing incidence of VS has been correlated to electromagnetic field (EMF) exposure, which might be considered a pathogenic cause of VS development and HL. Here, we explore the molecular mechanisms underlying the biologic changes of human SCs and/or their oncogenic transformation following EMF exposure. Through NGS technology and RNA-Seq transcriptomic analysis, we investigated the genomic profile and the differential display of HL-related genes after chronic EMF. We found that chronic EMF exposure modified the cell proliferation, in parallel with intracellular signaling and metabolic pathways changes, mostly related to translation and mitochondrial activities. Importantly, the expression of HL-related genes such as NEFL, TPRN, OTOGL, GJB2, and REST appeared to be deregulated in chronic EMF exposure. In conclusion, we suggest that, at a preclinical stage, EMF exposure might promote the transformation of VS cells and contribute to HL.
Identifiants
pubmed: 34360009
pii: cells10071840
doi: 10.3390/cells10071840
pmc: PMC8307028
pii:
doi:
Substances chimiques
GJB2 protein, human
0
Membrane Proteins
0
Neurofilament Proteins
0
OTOGL protein, human
0
Proteins
0
RE1-silencing transcription factor
0
Repressor Proteins
0
TPRN protein, human
0
neurofilament protein L
0
Connexin 26
127120-53-0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Capita Foundation
ID : grant 2019 to V.M.
Organisme : Università degli Studi di Milano
ID : grant PSR_VMAGN_2019 to V.M
Organisme : MIUR Italian Ministry of Research
ID : Progetto di Eccellenza
Références
Health Phys. 2007 Jun;92(6):609-20
pubmed: 17495663
J Vis Exp. 2014 Jul 20;(89):
pubmed: 25079666
Brain Res. 1989 Apr 24;485(2):309-16
pubmed: 2497929
J Neurosci. 2004 Mar 31;24(13):3186-98
pubmed: 15056698
Cell Death Discov. 2015 Sep 07;1:15021
pubmed: 27551454
Proc Natl Acad Sci U S A. 2010 Dec 7;107(49):21104-9
pubmed: 21078986
Hear Res. 2016 Mar;333:179-184
pubmed: 26850479
Nat Methods. 2017 Apr;14(4):417-419
pubmed: 28263959
Cell Mol Life Sci. 2020 Oct;77(20):4143-4161
pubmed: 31912196
Hear Res. 2014 Sep;315:25-33
pubmed: 24910344
Int J Mol Sci. 2020 Sep 11;21(18):
pubmed: 32933046
Tumour Biol. 2014 Jan;35(1):581-7
pubmed: 23975478
Indian J Exp Biol. 2013 Mar;51(3):187-200
pubmed: 23678539
Genet Test Mol Biomarkers. 2013 Aug;17(8):581-7
pubmed: 23738631
Mol Cancer Res. 2012 May;10(5):649-59
pubmed: 22426462
Cell Death Dis. 2015 Oct 15;6:e1915
pubmed: 26469964
Arch Intern Med. 2009 May 25;169(10):938-44
pubmed: 19468085
Neuroepidemiology. 2010 Aug;35(2):109-14
pubmed: 20551697
Cell. 2018 Jul 26;174(3):536-548.e21
pubmed: 29961578
Oncogene. 2010 Nov 25;29(47):6216-21
pubmed: 20729918
Int J Oncol. 1999 Mar;14(3):409-15
pubmed: 10024671
Pathophysiology. 2013 Apr;20(2):85-110
pubmed: 23261330
Am J Otol. 2000 May;21(3):405-11
pubmed: 10821556
Genome Biol. 2014;15(12):550
pubmed: 25516281
Head Neck Pathol. 2020 Dec;14(4):1058-1066
pubmed: 32232723
Nature. 1997 May 1;387(6628):80-3
pubmed: 9139825
Cancer Epidemiol. 2011 Oct;35(5):453-64
pubmed: 21862434
Nat Rev Neurosci. 2004 Jun;5(6):462-70
pubmed: 15152196
Otol Neurotol. 2005 Jan;26(1):93-7
pubmed: 15699726
Neural Dev. 2012 Nov 20;7:37
pubmed: 23167977
Biochim Biophys Acta. 2012 Dec;1826(2):400-6
pubmed: 22750751
Pathophysiology. 2009 Aug;16(2-3):113-22
pubmed: 19268551
J Neurosurg. 2014 Dec;121(6):1434-45
pubmed: 25245477
Curr Otorhinolaryngol Rep. 2018 Mar;6(1):15-23
pubmed: 31485383
Brain Res Mol Brain Res. 1998 Aug 31;59(2):229-46
pubmed: 9729404
Exp Neurol. 2010 Nov;226(1):173-82
pubmed: 20816824
Bioelectromagnetics. 1993;14(4):353-9
pubmed: 8216387
Int J Oncol. 2013 Oct;43(4):1036-44
pubmed: 23877578
J Neurochem. 2006 Oct;99(1):13-9
pubmed: 16899067
Nucleic Acids Res. 2001 May 1;29(9):e45
pubmed: 11328886
PLoS Genet. 2019 Feb 19;15(2):e1007982
pubmed: 30779743
Biol Bull. 2011 Aug;221(1):79-92
pubmed: 21876112
Lancet Oncol. 2011 Jul;12(7):624-6
pubmed: 21845765
Cells Tissues Organs. 2006;182(2):59-78
pubmed: 16804297
Neurosurgery. 2010 Nov;67(5):1335-40; discussion 1340
pubmed: 20871439
Otol Neurotol. 2011 Feb;32(2):308-14
pubmed: 21178801
Sci Rep. 2015 Dec 22;5:18599
pubmed: 26690506
Histol Histopathol. 2007 Jul;22(7):777-80
pubmed: 17455151
Int J Oncol. 2002 Mar;20(3):475-82
pubmed: 11836557
Curr Protein Pept Sci. 2010 Sep;11(6):471-84
pubmed: 20491622
Mol Cell Biol. 2009 Aug;29(15):4250-61
pubmed: 19451225
ASN Neuro. 2019 Jan-Dec;11:1759091419838949
pubmed: 31046408